Vortioxetine + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Post-COVID-19 Condition
Conditions
Post-COVID-19 Condition, Post-COVID-19 Syndrome, Cognitive Impairment
Trial Timeline
Sep 16, 2021 → Feb 22, 2023
NCT ID
NCT05047952About Vortioxetine + Placebo
Vortioxetine + Placebo is a phase 2 stage product being developed by Brain Biotech for Post-COVID-19 Condition. The current trial status is completed. This product is registered under clinical trial identifier NCT05047952. Target conditions include Post-COVID-19 Condition, Post-COVID-19 Syndrome, Cognitive Impairment.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05047952 | Phase 2 | Completed |
Competing Products
2 competing products in Post-COVID-19 Condition
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Nirmatrelvir/ritonavir + Placebo/ritonavir | Pfizer | Phase 2 | 51 |
| Meplazumab for injection | Pacific Biosciences | Phase 3 | 69 |